Anti-Human DKK1 Recombinant Antibody (BHQ880) (CAT#: TAB-214CL)

Figure 1 BHQ880 reverses the inhibitory effect of MM cells on osteoblastogenesis.

BMSC obtained from BM aspirate of MM patients were stimulated with OB differentiation media for 3 weeks in the presence of IgG1 isotype control antibody or 1 μg/mL BHQ880 and in the absence of INA-6 MM cells. At the end of the culture period, the cells were fixed in 10% formaldehyde and stained with Alizarin Red for 30 minutes.

Fulciniti, M., Tassone, P., Hideshima, T., Vallet, S., Nanjappa, P., Ettenberg, S. A., ... & Mitsiades, C. (2009). Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood, 114(2), 371-379.

Figure 2 BHQ880 reverses the inhibitory effect of MM cells on osteoblastogenesis.

Supernatants from these assays were analyzed for huIL-6 level by ELISA. IL-6 production was suppressed after treatment with BHQ880 in supernatants from both cultures with and without MM cells.

Fulciniti, M., Tassone, P., Hideshima, T., Vallet, S., Nanjappa, P., Ettenberg, S. A., ... & Mitsiades, C. (2009). Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood, 114(2), 371-379.

Figure 3 BHQ880 inhibits IL-6 production and MM cell adhesion and modulates β-catenin and NF-κB pathways in BMSC from MM patients.

Cytoplasmic fraction was subjected to immunoblotting using anti-phospho β-catenin antibody and anti–β-catenin antibody.

Fulciniti, M., Tassone, P., Hideshima, T., Vallet, S., Nanjappa, P., Ettenberg, S. A., ... & Mitsiades, C. (2009). Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood, 114(2), 371-379.

Figure 4 BHQ880 improves bone disease in a murine model of human MM.

One month after treatment, bone chips were retrieved and decalcified, and sections from BHQ880-treated bones were immunohistochemically stained for ALP. Sections were observed and photographed with a Nikon transmitted light microscope. Original magnification ×200.

Fulciniti, M., Tassone, P., Hideshima, T., Vallet, S., Nanjappa, P., Ettenberg, S. A., ... & Mitsiades, C. (2009). Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood, 114(2), 371-379.

Figure 1 Anti-Human DKK1 Therapeutic Antibody (TAB-214CL) in DB

Dot Blot analysis of TAB-214CL was performed by coating with human DKK1 protein (His tag).

TAB-214CL incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-Human IgG was used as a secondary antibody (1: 2000)

Figure 2 Anti-Human DKK1 Therapeutic Antibody (TAB-214CL) in WB

Western blot analysis of TAB-214CL was performed with human DKK1 protein onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with TAB-214CL and HRP goat anti-Human IgG was used as a secondary antibody (1: 2000). Chemiluminescent detection was performed.
Lane 1: Reduced antigen (0.1 μg)
Lane 2: Reduced antigen (0.3 μg)
Lane 3: Reduced antigen (0.6 μg)

Figure 3 Anti-Human DKK1 Therapeutic Antibody (TAB-214CL) in ELISA

ELISA analysis of TAB-214CL was performed by coating with human DKK1 protein (His tag). Then blocked with BSA and incubated with TAB-214CL. The HRP-conjugated goat anti-Human IgG was used as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.